ft 22 apr 93 survey pharmaceut research develop 8 select process critic winner loser decid develop crucial compon futur fortun pharmaceut group access either intern extern excit research way compani select new chemic entiti way develop decid sector winner loser develop process import differenti come way select research use creativ flexibl way explain dr rolf kreb chairman boehring ingelheim select compound far easi yet accord dr richard syke glaxo chief execut director r amp critic decis made critic decid project take forward know medic need know technolog feasibl innov drug must potenti import medicin signific advantag term safeti efficaci say dr syke r amp director agre compound must innov success industri gener enough innov product end fight cheap gener product say dr kreb defin let alon gener innov product easi howev problem know go elsewher say dr georg post r amp chairman smithklin beecham take tagamet anti ulcer product sale dollar 1bn year work began compound 30 year ago new chemic entiti like black box say dr post far clear work safe might behind three compani opposit second third compound could fall waysid explain gener compound set drug say dr post wrongli becom pejor term say dr leon rosenberg presid bristol myer squibb pharmaceut research institut scienc move small increment giant step made decad even everi 20 year world two top sell drug zantac vasotec compound dose safeti improv dr post agre point 25 32 compound given classif us food drug administr 1980 actual offer improv safeti toler qualiti life better dose earlier medicin develop innov drug riski molecul take longer develop too heighten danger cut reason safeti efficaci dr max wilhelm ciba say develop portfolio must balanc follow product case fail must also good mixtur safe bet high risk high reward product develop product reach annual sale sfr500m sometim innov justifi say dr wilhelm explain recent decis launch lotensin ace inhibitor hypertens even though market satur even price competit us argu develop drug gave compani access expert opinion former without lotensin ciba credibl cardiovascular market would undermin kept us market place scientif commun make money say dr wilhelm group far draconian approach dr frank joachim morich director pharmaceut r amp bayer say pleas compani fail figur among top 50 group list order number compound develop say relationship number compound develop innov dr jurgen drew presid intern r amp roch also becom increasingli tough becom vigor refus develop agent innov profil cut number compound develop 15 20 per cent past 12 16 month learn strict dr drew say increasingli larg proport molecul propos research reject reckon 10 year ago 10 per cent compound enter clinic develop made market barrier higher proport reach market 30 per cent fewer higher qualiti less attrit say ad complic develop process need conduct intern spite effort harmonis regul author us japan europ still often requir differ clinic trial given cost bring drug market pharmaceut group must develop medicin three region cover 80 per cent world market compani expertis begin licens product co develop other turn contract research organis bessalaar pharmaco us munich base harrison clinic research conduct clinic trial given increas demand regulatori group group look cut number studi complex studi conduct seduct conduct trial add supplementari question realli necessari creat enorm quantiti data analys say dr stephen hill medic director roch product roch uk subsidiari r amp director must also brutal cut project say dr syke glaxo compani ahead drug good need act noth wrong cut project decis made final end product good read say dr drew new drug applic must attract dossier must entertain valu must someth almost fun deal read faster investig becom involv posit way claim